Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving bevacizumab together with sorafenib works in
treating patients with unresectable stage III or stage IV malignant melanoma. Monoclonal
antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. Sorafenib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Bevacizumab and sorafenib may also stop
the growth of melanoma by blocking blood flow to the tumor. Giving bevacizumab together with
sorafenib may kill more tumor cells.